biostudies-literatureUnknown2(11)Mark PBVifor Fresenius Medical Care Renal PharmaKidney Research UK<h4>Background</h4>People with kidney failure treated with hemodialysis (HD) are at increased risk of stroke compared with similarly aged people with normal kidney function. One concern is that treatment of renal anemia might increase stroke risk. We studied risk factors for stroke in a prespecified secondary analysis of a randomized, controlled trial of intravenous iron treatment strategies in HD.<h4>Methods</h4>We analyzed data from the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial, focusing on variables associated with risk of stroke. The trial randomized 2141 adults who had started HD <12 months earlier and who were receiving an erythropoiesis-stimulating agent (ESA) to high-dose IV iron administered proactively or low-dose IV iron administered reactively in a 1:1Kidney3601761-1769https://www.ebi.ac.uk/biostudies/studies/S-EPMC8785850biostudies-literatureStroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.PMC8785850Ford IAkbani HBrown AKhwaja ARamadoss SSolomon LSevern AWheeler DCAyub WNeary JWalters MRBarratt JWinnett GLawman SHall MNicholas JDasgupta IMoriarty JMcMurray JJVBasanyake KConnor AVilar EHarty JPetrie MCWellberry-Smith MJhund PSMark PBConnolly EMacdougall ICBenzimra RAlchi BWinearls CGMcCafferty KBolton SPIVOTAL InvestigatorsGriffiths MMikhail AWessels JChowdury PSwift PBalasubramaniam GBanerjee DAnker SDBhandari SWhite CThomson PShivashankar GPower ATomson CRVMitra SRoss CKirk ALedson TWalsh SGoldsmith CStratton JDoyle AMaxwell PQuinn MDoulton TClarke HDay CSmith SBell SFarrington KRamakrishna BRobertson MJesky MKalra PABrown RfalseStroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.<h4>Background</h4>People with kidney failure treated with hemodialysis (HD) are at increased risk of stroke compared with similarly aged people with normal kidney function. One concern is that treatment of renal anemia might increase stroke risk. We studied risk factors for stroke in a prespecified secondary analysis of a randomized, controlled trial of intravenous iron treatment strategies in HD.<h4>Methods</h4>We analyzed data from the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial, focusing on variables associated with risk of stroke. The trial randomized 2141 adults who had started HD <12 months earlier and who were receiving an erythropoiesis-stimulating agent (ESA) to high-dose IV iron administered proactively or low-dose IV iron administered reactively in a 1:12021-01-01T00:00:00Z2021 Nov2026-05-09T09:30:33.627Z2025-04-04T22:04:17.602ZS-EPMC87858503537299210.34067/kid.000427202110.34067/KID.0004272021